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ABSTRACT 
 p53 is a tumor suppressor protein which orchestrates cell cycle arrest or apoptosis to 
prevent the hyperproliferation of cells which could lead to cancer. However, when p53 is 
inactivated, which happens in over 50% of cancers, it fails to induce PUMA, a potent apoptotic 
protein. Loss of PUMA makes cancer cells less likely to undergo apoptosis upon stress stimuli. 
Recent GRO-seq data revealed unique antisense transcription initiated 6kb into the PUMA 
locus, creating a small noncoding RNA transcript dubbed BAIT (BBC3 antisense intragenic 
transcript). This project focused on understanding the expression and function of BAIT, which 
we hypothesized could modulate the expression of the sense PUMA transcript. Using a 
luciferase reporter vector we showed that the proximal TATA box near the transcription start 
site for BAIT is necessary to drive its expression. We found that BAIT is expressed in different 
cell types and BAIT levels fluctuate in response to different stimuli. Surprisingly, we 
demonstrated BAIT expression is independent of p53, as elevated levels were observed in 
HCT116 p53 null cells. Finally, we observed that BAIT expression decreased upon activation of 
p53 by Nutlin as compared to basal conditions, and when BAIT is knocked down, the 
predominant PUMA transcript variant decreased. This provides the foundation for future 
studies to determine a mechanism for how BAIT contributes to the regulation of PUMA 
expression, which could illuminate strategies to induce PUMA expression and apoptosis in 
tumors with inactive p53.   
 
Key words: p53, apoptosis, PUMA, natural antisense transcription, noncoding RNAs, GRO-seq 
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INTRODUCTION 
Mutations that inactivate the protein p53 occur in over 50% of human cancers, 
highlighting the importance of studying this vital transcription factor and the gene networks it 
regulates. p53 is a transcription factor regulating genes that suppress tumor progression. 
Different types of cellular stress, such as DNA damage, oncogene hyperactivation or nutrient 
deprivation activate p53. In order to prevent cells with possible deleterious mutations from 
giving rise to cancer, p53 either induces cell cycle arrest, which coordinates the DNA repair 
pathways, or induces cell death (Weinberg 2006). p53 controls cell cycle proliferation by 
activating the p21 protein, which the inhibits the proteins necessary for cell cycle continuation. 
Activated p53 also regulates the gene locus for the p53 up-regulated modulator of apoptosis 
(PUMA). The PUMA protein is a key player in the balance of pro-survival and pro-apoptotic 
proteins guarding the release of inducible death factors from the mitochondria. Importantly, 
p53 largely determines a cell’s fate between life and death. When a mutation hinders its crucial 
functions, however, cells may gain the ability to proliferate indefinitely, which results in a tumor 
(Vousden 2009).  
 Wild-type p53 transactivates PUMA. When p53 is nonfunctional due to a mutation, less 
PUMA is generated and the likelihood of apoptosis decreases. If PUMA could become induced 
independently of p53, then novel cancer therapies could target this molecular pathway. As a 
result, the mechanism of PUMA activation is heavily studied. The gene that encodes PUMA is 
distinctive because unlike other p53 transcriptional targets, it has a large amount of RNA 
polymerase II (RNA Pol II) in the middle of the gene both before and after p53 activation. 
However, once p53 activates PUMA, the RNA Pol II moves through the remainder of the gene, 
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in the sense direction, generating the full-length pre-mRNA that can be fully processed and 
translated into the pro-death PUMA protein (Gomes and Espinosa 2010). GRO-seq data 
revealed antisense transcription beginning in intron 3 of PUMA, creating a non-coding RNA, 
dubbed BAIT (BBC3 antisense intragenic transcript) (Allen et al. 2014). Most interestingly, the 
BAIT antisense transcript begins in the same region of the PUMA locus as where we found 
accumulated RNA Pol II in the sense direction. BAIT is a natural antisense transcript (NAT) 
because its sequence aligns with the PUMA sense transcript. NATs are hypothesized to regulate 
their corresponding sense transcript target by affecting transcription, RNA processing and/or 
RNA export (Beiter 2008).  
 Currently, we hypothesize two alternative means by which BAIT may affect its 
corresponding sense transcript PUMA. The first is that the act of transcribing BAIT in the 
antisense direction regulates RNA Pol II’s movement along the DNA in the sense direction. 
Alternatively, the BAIT transcript itself may physically modulate the transcription of PUMA. In 
the latter hypothesis, a knockdown of BAIT anti-sense transcript would alter the relative 
amount of PUMA generated. Overall, characterizing BAIT contributes significantly to the 
growing knowledge on the mechanism of PUMA activation and regulation. 
BACKGROUND 
Prelude: Cancer and Gene Regulation 
In 2014, cancer caused 23% of the deaths in the United States, second to cardiovascular 
disease (WHO 2014). Based on the population of the United States, approximately 600,000 men 
and women were expected to die from cancer in 2014, with lung, prostate/breast, and colon 
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being the top three culprits (ACS 2014). Cancer is a disease that results from a malfunction of 
the genes that control cell growth and division. This misregulation creates unstoppable 
proliferation and can result in the phenotypically observable solid tumor mass. Environmental 
and lifestyle factors, carcinogenic agents, and genetic inheritances are all factors that can 
create somatic mutations that manipulate gene networks. Mutations in progenitor cells 
increase risk of indefinite propagation of those mutations via daughter cells. The mutations that 
occur in oncogenes or tumor suppressors are fundamental to tumor progression because they 
can result in an abnormal protein with a gain or loss of function (Weinberg 2006). Some key 
oncogenes are transcription factors that are constitutively activated to upregulate the 
expression of genes that cause cell proliferation. Conversely, mutations within transcription 
factors such as tumor suppressors may cause loss of function, rendering them unable to 
upregulate genes required to halt cell division. Although cells have mechanisms in place to 
prevent mutated cells from propagating errors, sometimes they occur within crucial genes that 
change the behavior of the normal cell and allow it to become cancerous. To understand and 
combat the mechanisms of cancer, investigations of both the normal gene networks and those 
gone astray due to gene mutations are important to develop therapeutics that can re-route the 
misregulation.  
An understanding of the normal gene regulatory methods that a cell uses to ward off 
transformation offers insight into how cancer can hijack this network to allow misregulation. 
Most simply, the nucleotide sequence of a specific gene contains two separate functional 
regions, the coding and noncoding control sequences (Karp 2009). The process of transcription, 
performed by the enzyme RNA polymerase II, copies the DNA sequence into an RNA sequence. 
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If this sequence is a coding transcript, it yields pre-mRNA comprised of both introns (noncoding 
region) and exons (coding region). The retained sequences, the exons, are joined together by 
removing the introns in a process termed splicing, creating messenger RNA (mRNA). Post-
transcriptional modifications for stability prepare the mRNA transcript for export into the 
cytoplasm where it undergoes translation into a protein, a process mediated by the ribosomes 
of the cell. In general, the expression of particular protein-coding genes is synthesized into a 
select cohort of proteins, which define the subset of phenotypes correlated to each specific cell 
type that are necessary for the development and function of different tissues comprising the 
organism.  
Additionally, the noncoding sequences and the transcription factors (proteins) dictate the 
precise expression of these genes. Transcription factors bind to a specific nucleotide sequence, 
or motif, where they foster or stifle expression of genes. This regulatory region of DNA is 
termed the enhancer, if it promotes gene expression, or repressor, if it inhibits it. These regions 
may be located upstream or downstream of the promoter region, or within the introns of the 
transcribed sequence. The promoter region contains ‘Core Promoter Elements’ (CPEs) such as 
the TATA box, which is recognized by the general transcription factor TATA binding protein 
(TBP) to define the transcription start site (TSS). Binding of general transcription factors to CPEs 
leads to recruitment of RNA polymerase II to the promoter region to initiate transcription. The 
high level of coordination between transcription factors, enzymes, and conserved regulatory 
sequences tightly controls the gene expression in a manner which preserves the longevity, 
vitality, and reproduction of the cell.  
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p53: Master Regulator of Life and Death 
 The p53 transcription factor has been dubbed the “Guardian of the Genome” since it 
masterfully orchestrates either cell cycle arrest or programmed cell death following exposure to 
various signals (Figure 1) (Vousden 2009). Acting as a transcription factor for a large number of 
genes, p53 prevents the continued growth of cancer cells (Weinberg 2006). In a cell, p53 levels 
rapidly increase in response to a multitude of cellular stresses, such as UV radiation, gamma-
irradiation, genomic mutations that lead to oncogene signaling, hypoxia, blockage of 
transcription, and genotoxic agents used in current cancer therapies (Attardi et al. 2000; Han 
2001; Ma et al. 2007; Sax et al. 2002). In the absence of stress stimuli, the E3 ubiquitin ligase, 
MDM2, targets p53 for degradation (Moll and Petrenko 2003). The drug Nutlin, a small 
molecule inhibitor of the MDM2-p53 interaction, directly induces p53 in experimental cell 
culture models and is also being tested in clinical trials (Vassilev et al. 2004). The extensive list 
of stimuli that can provoke induction of p53 clearly reveals that the cell is constantly monitoring 
its vitality and, in the presence of a hostile situation, deploys p53.  
 
Figure 1: Schematic of the Dual Functions of p53 – Protector and Killer. “In this model, basal p53 activity elicits the protector 
responses that support cell survival and promote the repair of genotoxic damage. Sustained stress or irreparable damage 
induces the killer functions of p53 to activate cell death or senescence. The protector functions of p53 contribute to tumor 
development if not properly regulated (red, dashed arrow)” (Vousden 2009). 
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 One of p53’s roles is also a healer; it halts cell cycle advancement by activating p21 and 
promoting the DNA damage repair process (Vousden 2009). The p21 protein functionally 
inhibits G1/S cyclin-dependent kinase 4, resulting in a temporary G1/S block in the cell cycle 
(Ball 1997). This pause in growth provides the opportune moment to either resolve DNA 
damage or safely wait for the removal of the stress stimuli. However, p21 can also contribute to 
a permanent variant of cell cycle arrest termed senescence. Indeed, p53-induced senescence is 
another mechanism in which precancerous cells can be restrained (Brown et al. 1997).  
 The alternative executioner function of p53 arises from its ability to coordinate 
apoptosis, the process of programmed cell death. A key mediator between p53 and its 
apoptotic activity is the protein PUMA (p53 upregulated modulator of apoptosis) which 
facilitates mitochondrial outer membrane permeabilization (Han et al. 2001; Nakano and 
Vousden 2001; Yu et al. 2001). It is now understood that extrinsic signaling and intracellular 
regulation of the mitochondrial components are two areas of regulation that p53 uses to elicit 
apoptosis (Haupt 2003).  
 Importantly, in almost every type of cancer there are significant rates of p53 
inactivation. In ovarian, esophageal, colorectal, head and neck, larynx, and lung cancers these 
mutations appear at rates from 38% - 90% (Olivier 2010). In cancers where p53 mutation is less 
common, other mechanisms have been shown to inactivate or inhibit its function. For example, 
frequently in cervical cancers the viral oncoprotein E6 degrades p53 (Tommasino 2003).  
Altering the function of p53 is thus advantageous for the development of cancer cells. This 
highlights the importance of understanding the regulatory pathways, mechanisms, and 
structures for the gene networks controlled by p53. 
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Skillful Execution by Apoptosis  
There are two arms to the apoptotic pathway, the intrinsic and extrinsic pathways. 
These pathways converge in activating caspases and result in the contained degradation of the 
cell’s vital components (Figure 2) (Haupt 2008).  
 
 
 
Figure 2: A model for p53-mediated apoptosis. (A) This model depicts the involvement of p53 in the extrinsic and intrinsic 
apoptotic pathways. p53 target genes are shown in red (Haupt 2003). (B) The zoomed in figure shows the balance between the 
pro-survival and pro-apoptotic proteins on the mitochondrial outer membrane (Research Apoptosis). In the presence of an 
apoptotic signal, cytochrome C is released into the cytoplasm resulting in apoptosis. 
 
The extrinsic apoptotic initiates via death receptors on the plasma membrane. The Fas 
receptor is recognized by the Fas ligand on T cells, which signals internal cell destruction (Muzio 
1998). In response to gamma-irradiation some cell types activate p53 to induce Fas mRNA 
expression (Bouvard et al. 2000). In addition to mRNA induction by p53, it has also been 
reported that p53 can increase trafficking of Fas within the Golgi to the plasma membrane 
surface. This interaction of p53 with Fas could allow rapid sensitization to Fas-induced 
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apoptosis. Another important member in the extrinsic pathway is the DR5/KILLER receptor 
which binds to the TNF-related apoptosis-inducing ligand (TRAIL). This receptor on the cell-
surface contains a death-domain which is responsible for inducing apoptosis (Attardi et al. 
2000). These important cell death receptors can respond to stimuli outside the cell to activate 
the caspase cascade (Muzio 1998) (Figure 2a). 
 The Bcl-2 family of proteins regulates the much more well-defined intrinsic apoptotic 
pathway (Hikisz 2012). There are two classes of proteins within the Bcl-2 family, the anti-
apoptotic (pro-survival) and pro-apoptotic members (Haupt 2003). The Bcl-2 pro-survival 
proteins, Bcl-2 and Bcl-XL, guard the mitochondrial membrane by preventing the pro-apoptotic 
family members from allowing cytochrome c and other death-inducing factors to be released 
into the cytosol (Figure 2b). Bcl-2 and Bcl-XL structurally contain the domains BH1, BH2, BH3, 
and BH4. The pro-apoptotic proteins, Bax and Bak, are structurally similar to Bcl-2 and Bcl-XL, 
but when inhibited by Bcl-2 and Bcl-XL, under normal growth conditions, they are unable to 
function. At the outer mitochondrial membrane, the pro-survival and pro-death proteins’ 
actions are balanced to tip towards pro-survival, yet in stress situations, the balance tips 
towards apoptosis (Han et al. 2001). There are also known pro-apoptotic proteins that contain 
only the BH3 domain, such as PUMA, NOXA, and Bik (Haupt 2003). These unique pro-apoptotic 
proteins form heterodimers with the pro-survival Bcl-2 members, restricting their function, thus 
allowing the pro-apoptotic Bcl-2 proteins to mediate apoptosis. Upon PUMA expression, Bax 
translocates to the mitochondria and multimerizes with Bak to form a pore, releasing 
cytochrome c from the inner mitochondrial membrane, a process termed mitochondrial 
permeabilization. NOXA also contributes to permeabilization in a manner similar to PUMA. 
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Thus, the induction of PUMA and NOXA is sufficient to shift the balance away from survival 
(Figure 2b). Within the cytosol, cytochrome c joins with apoptotic protease-activating factor 1 
(APAF-1) and procaspase-9 to form a complex known as the apoptosome (MacLachlan and El-
Deiry 2002; Hikisz 2012). This complex is then able to activate the pro-effector caspases, which 
are activated by both the intrinsic and extrinsic apoptotic pathways.  
 The final essential member to the cell’s fatal outcome is the pro-apoptotic protein Bid 
(Bcl-2 interacting domain death agonist) which is one possible link between the extrinsic and 
intrinsic apoptotic pathways. Caspase-8 (the initiator caspase activated by the cell-membrane 
receptors) cleaves Bid and exposes its N-terminal glycine residue. This new form of Bid is able 
to translocate and insert into the mitochondria, resulting in Bax and Bak activation. 
Importantly, Bid-null cells are resistant to drugs such as 5-fluorouracil indicating Bid as a key 
player in this pathway (Sax et al. 2002).  
 Once caspase activation has begun, the downward spiral to apoptosis is irreversible. 
Caspases-8 and -10 are the caspases activated from the death receptor pathway, and caspase-9 
becomes activated when the apoptosome forms. These initiator caspases then begin the 
caspase cascade by cleaving the pro-effector caspases into their mature form, resulting in the 
activation of effector caspases, such as caspase-3, -6 and -7 (MacLachlan and El-Deiry 2002; 
Apoptotic Signaling Pathwyas 2012). The effector caspases work to digest essential targets of 
cell viability resulting in the controlled and contained cell death, apoptosis. Hence, a better 
understanding of apoptosis induction specific to the stage, tissue, and stress-signal could 
provide target areas for cancer therapies. 
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PUMA: The King of the Mitochondrial Jungle 
 PUMA is a potent pro-apoptotic protein that can bind to all the pro-survival Bcl-2 family 
members to antagonize their function. PUMA was independently discovered in two laboratories 
and its gene BBC3 (Bcl-2 binding component 3) was also identified by another method at about 
the same time (Yu et al. 2001; Nakano and Vousden 2001; Han et al. 2001). Nakano and 
Vousden showed that “induction of p53 by doxorubicin or actinomycin D elevates PUMA levels” 
(2001). The Vogelstein laboratory reported that the spliced mRNA transcript of PUMA is 1.6 – 
1.9Kb with four exons (1a, 2, 3, and 4) and an initiation codon in exon 2 (Figure 3).  
 
Figure 3: PUMA gene and protein structure. The human PUMA gene contains three coding exons (exons 2–4) and two 
noncoding exons (exons 1a and b). The binding site of p53 is found in the regulatory regions of both human and mouse genes 
upstream of exon 1a. PUMA transcript variant 4 is generated from the locus. This PUMA protein variant has two functional 
domains, the BH3 domain and a C-terminal mitochondria-localization signal (MLS), both residing in exon 3. Alignment of the 
BH3 domain of PUMA with those of other proapoptotic Bcl-2 family members is shown with the conserved residues shaded in 
gray. (Adapted from Yu and Zhang 2008 and Gomes and Espinosa 2010). 
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PUMA’s BH3 domain is encoded by the third exon and the amino acid sequence of this domain 
aligns with the BH3 domains of the other pro-apoptotic proteins. Moreover, in exon 3 PUMA 
contains a mitochondrial localization signal (MLS) to guide PUMA to the mitochondria. Two 
different isoforms of PUMA protein, PUMA α and β, contain the BH3 and MLS domain required 
for PUMA function. However, PUMA α is generally the more abundant of the two and is more 
readily upregulated during the p53 response. The PUMA variant 4 protein is produced from 
PUMA α mRNA and this form is able to elicit p53-mediated apoptosis (Figure 3). The BH3 
domain of PUMA is able to insert into the hydrophobic pocket of the folded BH1, BH2, and BH3 
domains of the Bcl-2 pro-survival family members, inhibiting their function (Borner 2003).  
 PUMA is a potent apoptotic protein. When exposed to genotoxic agents PUMA null 
colorectal cancer cells (HCT116 PUMA -/-) are unable to enter apoptosis (Yu and Zang 2008). 
Furthermore, HCT116 PUMA +/+ cells, that have a targeted deletion of the p53-binding sites in 
the PUMA promoter, fail to elicit apoptosis in the presence of p53 when exposed to DNA 
damage (Wang et al. 2007). Compiling these results reveals that p53 binding to the PUMA 
promoter is a major driver for transcription activation of PUMA and that PUMA is a key 
contributor to p53-mediated apoptosis. Alternatively, data revealed other transcription factors 
such as FOXO3a, SP1, or p73 are sufficient to activate PUMA in a manner that is p53-
independent during cytokine/growth factor withdrawal (Han 2001; Ming 2008; You 2006). 
PUMA therefore is a critical protein that is regulated by diverse cell death and survival signals to 
promote apoptosis, which may contribute to suppressing carcinogenesis. PUMA also might 
work as a target for eliciting cell death in cancer cells, which has been demonstrated by BH3 
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mimetics, a class of cancer drugs which mimic the function of the BH3 domain to inhibit pro-
survival proteins (Chonghaile and Letai 2009). 
Making Sense of Antisense Transcription 
 The first draft of the human genome sequence revolutionized the molecular biology 
field (Lander 2001). Since then, two unexpected findings have radically changed the 
understanding of the genome. The first unexpected fact was that the number of protein-coding 
genes was much lower than anticipated, only about 21,000 (Consortium 2004). Pre-mRNA 
alternative splicing and post-transcriptional modifications of RNA have been proposed as 
mechanisms by which cells were able to create a large repertoire of proteins, leading to the 
larger molecular and cellular complexity separating Homo sapiens from organisms such as C. 
elegans. The second discovery was that over 90% of the transcribed material within the 
genome are non-coding RNAs (ncRNAs) (Mattick and Makunin 2006; Prasanth and Spector 
2007). Current hypotheses pose that an additional level of genomic complexity resides with 
these ncRNAs. A fraction of these ncRNAs are complementary to other endogenous RNAs and 
are termed natural antisense transcripts (NATs). The antisense transcription that is naturally 
occurring in eukaryotes has been considered an important feature in the gene network, 
increasing the cellular and organismal complexity through regulation of sense RNA processing, 
sense RNA export and mechanisms such as sense transcriptional regulation (Beiter 2008; Wight 
and Werner 2013).  
 DNA is famously known for its double-helix structure comprised of two nucleic acid 
strands in an anti-parallel orientation. Conventionally, one of these strands is designated as the 
sense strand, which often is the strand that codes for a protein, while the other generally non-
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coding strand is the antisense strand. Usually, the sense strand is transcribed more abundantly, 
undergoes splicing, contains introns, and generates a protein with a known function (Munroe 
2006; Chen 2005). When natural antisense transcription occurs and can be correlated by 
sequence pairing to a sense transcript, this is defined as a sense-antisense (SAS) pair. 
 NATS are both abundant and diverse throughout the genome (Kapranov et al. 2007; 
Yelin et al. 2003). It has been reported that NATs lack polyadenylation and are usually restricted 
to the nucleus (Oeder et al. 2007). Polyadenylation is a post-transcriptional modification to the 
RNA which prevents the degradation of the transcript, thus increasing the transcripts’ stability. 
The lack of polyadenylation in most NATs signifies that these transcripts are potentially 
unstable transcripts.  Two different types of NATs have been defined by their relation to the 
sense strand (Li et al. 2006). Cis-NATs are defined as transcripts generated from the opposite 
strand of DNA at the same locus that creates the sense RNA. These are the most commonly 
observed and the easiest to distinguish. Less typical are trans-NATs which are transcribed away 
from the gene locus that they regulate and contain sporadic complementary sequences to the 
corresponding sense transcript. Moreover, NATs are divided into categories based on their 
orientation relative to the sense strand. Overlapping 5’ ends or the beginning of transcription 
are termed divergent, overlapping 3’ ends or the end of transcription are termed convergent, 
and embedded defines when one gene is included in the region of another (Lapidot and Pilpel 
2006). There is no dominating pattern to the overlapping structure of the NATs and little 
consensus in the field regarding the ways to define these types of transcripts. 
 Large-scale genomics experiments have led to the discovery of many NATs. However, 
experimental validation that demonstrates a functional impact on their corresponding sense 
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strand counterparts has been shown for only a few NATs (Beiter 2008). NAT function is quite 
difficult to assess experimentally because NATs can be expressed differently between tissue 
types and distinct stimuli. Furthermore, if this expression change is correlated, positive or 
negative, to the expression of their sense counterpart, it does not necessarily imply a regulatory 
interaction (Beiter 2008).   
 SAS pairs have been reported to exhibit both linear and reciprocal expression patterns 
(Chen et al. 2005; Oeder et al. 2007). The inconsistency observed in positive or negative 
patterns for SAS pairs suggests that NATs may have multiple mechanisms to regulate their 
sense strand transcription. A possible hypothesis for NATs function is post-transcriptional 
masking of key regulatory features to inhibit splicing, export, and transcript stability (Figure 4a). 
Genomic analysis of these functions showed SAS overlapping patterns at the exon-intron 
border. Two studies have revealed this link, the RevErbAs transcript and Zeb2na transcript, both 
of which inhibit intrinsic splicing (Hasting 2008; Beltran 2008). Alternatively, RNA interference 
and RNA editing creating small-RNA based gene silencing pathways is speculated to be an 
additional role of SAS pairs as observed in plants, flies, and mammals (Neeman et al. 2005; 
Borsani et al. 2005; Watarabe 2008) (Figure 4b). These NATs can form intramolecular hairpin 
structures, such as short interfering RNAs (siRNAs) or microRNAs (miRNAs) that could be 
substrates for Dicers which degrade mRNA (Borsani et al. 2005).  
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Figure 4: “(A) RNA masking: A cis-regulatory element in the sense transcript (blue) is masked by hybridization with the natural 
antisense transcript (NAT) (red). In this example, sense-antisense (SAS) duplex formation prevents binding of the spliceosome, 
and consequently, the intron is retained. (B) A-to-I editing and RNA interference: Like intramolecular hairpin structures, 
intermolecular SAS RNA duplexes might constitute potential substrates for RNA-processing enzymes like ADAR and DICER.” 
(Beiter 2008). 
 
Transcription of the anti-sense strand could also suffice to interfere and suppress sense 
transcription (Shearwin et al. 2005) (Figure 5a). This could occur at initiation of transcription 
from competition for RNA Pol II and the binding of other transcription factors, or during 
elongation when the RNA Pol II on each strand collides (Hobson 2012).  
Michael 19 
 
 
 
Figure 5: “(A) Transcriptional interference: Elongating polymerase from one gene directly interferes with transcription 
elongation (left) or initiation (right) of an overlapping transcriptional unit. (B) Epigenetic modification: The NAT forms a 
structure that is recognized by distinct histone-modifying complexes. Recruited complexes can act in cis or may be guided by 
the ncRNA to distant genomic loci” (Beiter 2008). 
 
Finally, NATs may function as a guide RNA to recruit or inhibit effector-complexes, such 
as chromatin remodeling complexes, to the sense strand (Figure 5b). Yu et al. reported a p15 
NAT able to silence transcription of p15 through heterochromatin formation (Yu et al. 2008). 
Chromatin complexes can generate a dynamic state coordinated by nucleosome positioning, 
chromatin associated proteins, chromatin remodeling, and histone modifications (Trojer and 
Reinberg 2007). The more tightly packed the DNA is into a heterochromatin formation, the less 
accessible it is to regulatory elements. Thus the gene is repressed. Nucleosomes and 
Michael 20 
 
methylation of histones (H3K9 and H3K20) classifies an inactive DNA region and consequently 
gene silencing (Kouzarides 2007; Barski et al. 2007). Conversely, acetylated histones, 
dimethylated histones (H3K4me2), and elongation histone markers (H3K79me2 and H3K36me3) 
are hallmarks of actively transcribed genes (Barski et al. 2007; Kouzarides 2007; Weber et al. 
2007). Some NATs are postulated to guide DNA- and histone- modifying enzymes to specific 
genomic loci, which could deliberately or incidentally alter the expression of adjacent 
transcribed regions (Beiter et al. 2008). Additional roles for NATs have also been reported to be 
play a role in X chromosome inactivation, genomic imprinting, regulation of monoallelic 
expression, and developmental control (Beiter 2008).  
 As genome wide experiments provide evidence of NATs, the challenge now is to validate 
them. The struggle in establishing physiological relevance to these transcripts remains in the 
instability, overlap with other transcripts, and tight balance of sense-antisense pairs that 
change between conditions. Nevertheless, studies have begun to pave the road into the 
scrambled ncRNA realm and provide further areas of unchartered territory to be researched.  
PRELIMINARY STUDIES 
 The Espinosa Laboratory primarily investigates the gene networks mainly controlled by 
p53, in hopes of defining mechanisms and discovering new proteins that could provide insight 
into a potential therapeutic strategy to combat cancer. The lab utilized a new technique, called 
Global Run-On sequencing (GRO-seq), to investigate the p53 transcriptional program (Allen et 
al. 2014). In this method, active RNA polymerase runs in the presence of Br-UTP, which is 
incorporated into the RNA sequence. Br-UTP antibodies are used to enrich the newly 
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synthesized RNA, which is then converted into cDNA. Deep sequencing of the cDNA reveals the 
sequences of RNAs that were being actively transcribed by RNA Pol II at the time of the 
experiment (Heinz et al. 2013). This technique is distinct in comparison to other RNA Pol II 
mapping methods because it only detects actively transcribed regions and it can differentiate 
between sense and antisense transcripts on a genome wide scale. Specifically, the Espinosa lab 
used GRO-seq to conduct a genome-wide analysis on HCT116 cells (p53 +/+ and -/-) in DMSO 
(Vehicle) compared to Nutlin treatment (Allen et al. 2014).  
 
Figure 6: GRO-seq of the p21 (CDKN1A) locus. Analysis of a common GRO-seq read for the p21 locus, a p53 target, with sense 
transcription (blue) increasing drastically after addition of Nutlin/activation by p53.  Low levels of antisense transcription (red) 
occurs upstream of transcription start site (Allen et al. 2014) 
 
Generally p53 was shown to activate hundreds of genomic loci after Nutlin addition. The 
p21 (CDKN1A) locus demonstrated a common GRO-seq result observed in many of the known 
p53 targets. GRO-seq revealed an increase in sense transcription in the presence of Nutlin-
induced p53 activation, and low level of antisense transcription occurring upstream of the 
transcription start site (Figure 6). This technique also uncovered many regions of antisense 
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transcription, bidirectional promoters (overlapping and non-overlapping), clustered 
transactivation, and eRNAs from p53 response elements. Among the subset of antisense 
transcription that was observed throughout the genome, notable robust antisense transcription 
occurred at the PUMA (BBC3) locus beginning just after exon 3 (Figure 7).  
 
 
 
Figure 7: GRO-seq of the BBC3 locus. (A) The GRO-seq analysis showed an increase in eRNA level in the presence of p53 
activated by Nutlin. Antisense RNA was also detected in high levels beginning after exon 3 (Allen et al. 2014). (B) Represents the 
BBC3 locus with the exons labeled. It is zoomed in to show where BAIT transcription begins relative to exon 3.  
 
Thus GRO-seq revealed a NAT candidate for PUMA, termed BAIT (BBC3 antisense 
intragenic transcript). The question for this specific NAT candidate then arose; does BAIT have a 
functional relevance to the regulation of the PUMA transcript?   
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RESEARCH AIMS 
GRO-seq data identified an antisense transcript, BAIT, which emerges after exon 3 of 
PUMA, revealing a NAT candidate for PUMA. NATs have been reported to be an important 
feature in the gene network by exhibiting regulatory mechanisms that contribute to the 
expression patterns of the sense transcript. This investigation characterizes the functionality of 
the BAIT promoter region and explores the relationship of the BAIT transcript to the sense 
transcription of PUMA.   
Aim 1: To investigate the function of the TATA box within the BAIT promoter region.  
Analysis of the genomic sequence upstream of BAIT transcription start site, identified by 
GRO-seq, revealed two possible TATA boxes. This suggested that BAIT harbors a promoter 
region necessary for its transcription. A study on the specificity of the TBP to the canonical 
TATA box sequence (TATAAAG) revealed which point mutations in the TATA box decrease the 
specificity of TBP to bind the TATA box, and thus reduce transcription (Wobbe and Struhl 1990). 
Applying this information to the sequences of the two putative TATA boxes upstream of BAIT 
TSS, the proximal TATA box (TATATGA) differs from the canonical sequence by two nucleotides 
that decreases its specificity by over 50% in vitro, while the distal TATA box (TATAAAT) does not 
differ and has 100% TBP specificity. Of note, changing the third T to an A, or the fourth A to a G, 
was shown to decrease TBP specificity to less than 1%. Using this info, we engineered four 
mutant TATA boxes within BAIT’s promoter region to test their functional activity in a luciferase 
reporter system (Figure 8).  
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Aim 2: To define BAIT expression patterns across cell types and stimuli.  
 It has been observed in previous studies on NATs that their expression level changes in 
response to different cell types and stimuli (Beiter 2008). Thus, we investigated how BAIT 
expression changes among different cell lines and under different DNA damage treatments. The 
amount of BAIT expression was quantitatively determined by analysis using strand-specific qRT-
PCR for BAIT.  
Aim 3: To define the impact of BAIT knockdown on PUMA expression.  
 To determine whether the BAIT transcript has a functional role in PUMA transcript 
expression, we used anti-sense oligonucleotides to knockdown BAIT. The knockdown was 
validated using qRT-PCR with a strand-specific primer for BAIT. The expression of PUMA was 
measured using primers for the PUMA exon 2:3 junction and exon 3:4 junction. These two 
junctions were specifically analyzed because BAIT transcription begins in intron 3 and thus 
could be altering either the PUMA exon 2:3 upstream junction or the exon 3:4 downstream 
junction in cis.  
 
METHODS 
Cell Lines and Culture 
 All cells were obtained from the Espinosa laboratory stocks. Each cell line was grown in 
the specified media (Life Technologies) supplemented with 10% fetal bovine serum (Sigma-
Aldrich) and 1% Antibiotic/Antimycotic solution (Life Technologies). The cultures were 
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incubated at 37˚C with 5% CO2. HCT116 p53 +/+ cell line was used for every experiment, except 
when specified otherwise.  
Table 1: Cell lines 
Cell Line  Media Tissue Disease 
A549 F-12:DMEM Lung Carcinoma 
IMR90 DMEM Fetal Lung  Normal  
SJSA RPMI Bone Osteosarcoma; Multipotential Sarcoma 
LnCap RPMI Prostate Prostatic Adenocarcinoma 
H460 RPMI Lung Carcinoma; Large Cell Lung Cancer 
U20S McCoy's 5A Bone Osteosarcoma 
MCF7 MEM Breast  Breast Adenocarcinoma 
HCT116 p53 +/+ McCoy's 5A Colon Colorectal Carcinoma 
HCT116 p53  -/- McCoy's 5A Colon Colorectal Carcinoma 
 
Drug Treatment 
 HCT116 cells were seeded in 10 cm plates at 4 million cells per plate. 24 hours later they 
were treated with 10 μM of Nutlin-3R, 375 μM of 5FU, 10 Gys of Gamma-irradiation (Tin Tin Su 
Laboratory, University of Colorado Boulder), 50 J/m2 of UVC, 79 μL Lipofectamine LTX with 73 
μL Plus Reagent (Life Technologies), the equivalent amount of vehicle (DMSO – Sigma-Aldrich), 
or untreated. The cells were harvested 16 hours post treatment. Veronica Dengler treated 
HCT116 p53 +/+ and p53 -/- cells with 375 μM of 5FU, 0.6 μg/mL of Doxorubicin (in water), or 
the equivalent amount of DMSO. She harvested her cells at 12 hours post treatment. I used the 
RNA she extracted from those cells for subsequent analysis (Figure 13).  
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Luciferase Assay 
 Dr. Mellert cloned the WT 257 bp region of the putative BAIT promoter containing the 
distal and proximal TATA boxes into the pGL3-Basic vector for the luciferase reporter system 
(Promega). This plasmid was used as a template for mutagenesis by PCR-driven overlap 
extension which introduced the T to A or A to G TATA box mutation (Heckman and Pease 2007). 
Dr. Mellert designed primers for PCR with the TATA boxes mutations in primer B and primer C 
for each mutation (T159A, A160G, T175A, A176G) and a primer to anneal on the opposite 
strand (primer A and primer D). The first PCR amplified the sequences between primers A and B 
creating product AB and added a KpnI restriction enzyme site. The first PCR also amplified 
between primers C and D creating product CD and the restriction site for HindIII. The PCR 
products were ran through DNA gel electrophoresis. The QIAEX gel extraction kit (Qiagen) was 
used to extract and purify the AB and CD products each harboring the mutations, T159A, 
A160G, T175A, or A176G. Then the AB and CD strands were annealed together in the second 
PCR using the primers A and D, resulting in an AD product. The most optimal DNA amounts 
used for the second PCR were 150 ng AB and 150 ng CD for the T175A mutant, and 200 ng AB 
and 100 ng CD for the A176G mutant. Importantly, Dr. Mellert performed the cloning for the 
T159A and A160G inserts and I performed the cloning for the T175A and A176G inserts. The 
PCRs were isolated through gel electrophoresis and the final AD products were extracted and 
purified as above, each harboring the 257 bp inserts, T159A, A160G, T175A, or A176G. The 
pGL3 plasmid and insert PCR products were digested with KpnI and HindIII enzymes. The pGL3 
vector (1000 ng) was then ligated to the AD insert product (160 ng) with T4 ligase (New England 
Biolabs). The products of the ligations (15 uL) were transformed into DH5α super competent 
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bacteria. Single colonies of bacteria were cultured for a mini-prep (Qiagen), test digested, and 
sent for sequencing. The plasmids with the correct sequences were amplified in DH5α cells and 
extracted from bacteria by midi-prep (Qiagen). The extracted plasmids were brought to a final 
concentration of 95 ng/μL (measured using the Qubit fluorometer for precise DNA 
concentrations).  
 These plasmids, along with the pGL3 basic vector or the p21-luciferase construct (el-
Deiry et. Al 1993) were transfected into HCT116 cells using PEI at three concentrations (0.5 μg, 
1.0 μg, or 2.0 μg) along with pCMV-LacZ as an internal control (always at 0.5 μg). The HCT116 
cells were seeded into a 6 well plate at 400,000 cells per well. 24 hours post-transfection, the 
cells were harvested in a lysis solution and processed for luciferase activity using the Dual-Light 
System (Applied Biosystems), following the manufactures guidelines. Each experiment was 
done in triplicates and three biological replicates were performed. The data were within the 
linear range, which was measured empirically using a dilution curve for the relative light units 
of luciferase and β-gal expression.  
 
Antisense Oligonucleotide Knockdown 
 We seeded 400,000 HCT116 cells into 6 well plates. 24 hours later we transfected the 
HCT116 cells with 200 nM of antisense oligonucleotide (ASO), 15 μL Lipofectamine LTX, 10 μL 
Plus Reagent, and brought to 300 μL volume with Opti-mem media (Life Technologies). We 
followed the Lipofectamine LTX+ protocol (Invitrogen) for an optimal transfection. To visually 
observe the transfection with fluorescence microscopy, we tagged the 5’end of a separate NT 
ASO with the thiol-reactive label, Texas Red Malemide, according to the manufactures 
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instructions (Vector Laboratories). 4 hours post-transfection we changed the media to 
complete McCoy’s media. 12 hours post-transfection we treated the cells with 10 μM Nutlin, or 
the equivalent amount of DMSO (vehicle). 24 hours post-transfection we harvested the cells. 
The knockdown was validated using qRT-PCR analysis of the extracted RNA. The ASO sequences 
were obtained from ISIS Pharmaceuticals ® as collaboration (Figure 14).  
Table 2: ASO sequences 
ASO distance from BAIT TSS Sample Number Sequence 
NT 141923 CCTTCCCTGAAGGTTCCTCC 
+18 710884 GGGCGCCGGCGCCCGGTGCC 
+22 710886 GCCGGCGCCCGGTGCCCGCG 
+46 710898 GAGGTGAGGAGCCGCCGGAT 
+182 710934 GGACAGGCGCCTCGCTGGGT 
+610 710956 AGCGATCACTCAGTTAAACA 
 
RNA Isolation and qRT-PCR Analysis 
 To isolate the RNA, cells were washed with PBS and lysed with TriZol reagent (Life 
Technologies). The RNA from the samples was extracted according to standard RNA extraction 
protocols and quantified using the Gen5 microplate spectrophotometrer (BioTek). The samples 
were then converted to cDNA using the qScript Flex cDNA Synthesis Kit (Quanta Biosciences). 
Two cDNA reactions were performed for each RNA sample.  
One cDNA reaction used the reaction protocol for Oligo dT and Random Primers, 
converting 1 ug of RNA into cDNA. The cDNA samples created from Oligo dT/Random primers 
were used in qRT-PCR reactions to measure the relative RNA content for PUMA exon 2:3 splice 
junction, PUMA exon 3:4 splice junction, p21, and 18s. The quantitative reverse transcriptase 
PCR (qRT-PCR) sample pates were prepared with SYBR Green I (Applied Biosystems), 1 ng/uL 
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cDNA, and 500 nM primer mixes. A standard curve from .02 to 20 ng of pooled cDNA was used. 
Values were normalized to those of 18s rRNA. 
The other cDNA reaction used the reaction protocol for Gene-Specific Priming, using a 
strand specific primer to BAIT (ssRT). The strand specific primer sequence is 
GTCCCTGGCCCTGGCCCTG. These cDNA samples were used in qRT-PCR reactions to measure the 
relative RNA content for BAIT. The qRT-PCR reactions were prepared with SYBR Green I, 20 
ng/uL cDNA, and 500 nM primer mixes. A standard curve from 0.1 to 100 ng of pooled cDNA 
was used. Values were normalized to those of 18s rRNA, measured from the same RNA sample 
with the cDNA Oligo dT/Random Primer reaction. 
Table 3: qRT-PCR primer sequences 
Primer Name Forward Primer 
Sequence (5’- 3’) 
Reverse Primer 
Sequence (5’-3’) 
BAIT GCGCAGCTCCACTCCTCGG GCCAGGGCCAGGGACTAGG 
PUMA E2:E3 GACGGTCCTCAGCCCTCGC GGCGACTCCAGGTGCTGCTC 
PUMA E3:E4 GACGACCTCAACGCACAGTA CCGGGGTACCACTAGGCCGCCG 
p21 CTGGAGACTCTCAGGGTCGAAA GATTAGGGCTTCCTCTTGGAGAA 
18s GCCGCTAGAGGTGAAATTCTTG CTTTCGCTCTGGTCCGTCTT 
Each qRT-PCR reaction was prepared on 384-well plates using the Eppendorf epMotion 5070 
robot. The plates were analyzed by the Applied Biosystems ViiA7 QRT-PCR machine (Life 
Technologies). 
 
Protein Isolation and Immunoblot Analysis 
 The cells which were treated with different stressors were harvested for protein and 
RNA. The apoptotic cells in the media were collected, and the cells on the plate were washed 
with PBS then scraped and added to the solution. The cells were pelleted by centrifugation at 
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1400 x g for 5 minutes. The pellet was homogenized in 1 mL of PBS. This solution was split in 
half, 500 uL for protein extraction, and 500 uL for RNA extraction. The cells were spun for 5 
minutes at 3,000 x g, and the PBS was aspirated off. The RNA half was extracted according to 
the RNA extraction protocol. The protein half was lysed in 200 uL lysis solution (1% SDS, 10% 
Glycerolin 100 mM Tris buffer, pH 7.45). Protein samples were sonicated and then centrifuged 
to remove any insoluble material. The supernatant was removed and quantified by BCA protein 
assay (Pierce). Samples were normalized to 1 μg/uL. 30 μg of protein was loaded per SDS-PAGE 
gel. p21 and α-tubulin western blots were run on a 12% SDS-PAGE gel. PUMA and p53 western 
blots were run on a 15% SDS-PAGE. Both SDS-PAGE gels were transferred to a 0.2 μm PVDF 
membrane.  
Table 4: Primary antibodies for western blots 
Primary Antibody: 
 
Company Catalog Number 
p53 Calbiochem OP43 
PUMA Santa Cruz Sc-28226 
p21 Santa Cruz Sc-817 
α-tubulin Sigma T9026 
The western blots were developed with peroxidase-conjugated secondary antibodies (Santa 
Cruz) and ECL detection agents (made in house) and viewed using an ImageQuant LAS4000 
digital camera system.  
 
Statistical Analysis 
 Each experiment was done in triplicates with three biological replicates (n=9). All 
statistical analysis for quantitative data was done in Excel. Standard error of the mean was used 
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to calculate the error between the three biological replicates. The formula used was the 
standard deviation of the normalized samples divided by the square root of the number of 
samples (3 BR). The Student’s T-test was used to determine whether the distribution of samples 
was statistically significant from the control sample (indicated in the figures for each 
experiment). The p-value resulting from the T-test needed to be less than 0.05 to be considered 
significant. All significant values with p < 0.05 are marked with an asterisk (*).   
  
 
RESULTS 
Aim 1: Two TATA boxes within the BAIT promoter region drive luciferase reporter expression.  
Luciferase Reporter Design 
GRO-seq analysis identified a region of active RNA Pol II on the antisense strand of 
PUMA that begins after the third exon which revealed regionally where the antisense strand 
begins. Further analysis of the genomic sequence upstream of this region, in the antisense 
orientation, identified two putative TATA boxes. These are termed the proximal and distal TATA 
boxes in relation to the transcription start site of the BAIT promoter region (Figure 8A).  Since 
the functional activities of these TATA boxes are unknown, we designed an experiment to 
investigate their activity in cells using the pGL3 Luciferase Reporter Vector system. Two 
different mutations were engineered for each TATA box (Figure 8A). The proximal TATA box 
was designed to have its third T switch to an A (T175A) and it’s forth A to a G (A176G). Similarly, 
the distal TATA box was designed to have its third T switch to an A (T159A) and it’s forth A to a 
G (A160G). These modifications of the TATA box have previously been shown to eliminate 
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binding of TBP (< 0.1%) which diminishes promoter activity (Wobbe and Struhl 1990). The pGL3 
plasmid was used as a backbone for the WT or mutant promoter regions to be inserted at the 
KpnI and Hind III restriction sites (Figure 8B). The vector without a promoter sequence and 
vector with the p21 promoter sequence (WWC LUC) were used as controls in this experiment.  
 
 
Figure 8: Model of the pGL3 Luciferase Reporter Vector with the select mutated BAIT promoter insert. A The sequence of the 
BAIT promoter region. This is in the antisense orientation of the PUMA sense sequence. The location of the distal and proximal 
TATA box is indicated. The four mutations were created in this WT sequence: Distal – T159A and A160G. Proximal – T175A and 
A176G. B Representation of the pGL3 Luciferase Reporter Vector and the location for the insert of the promoter region with 
mutations using the KpnI and HindIII restriction sites.  
 
Luciferase assays were performed in HCT116 cells expressing the pGL3 Plasmid and a 
Lac-Z construct for the combined detection of the luciferase and β-galactosidase gene products. 
The Lac-Z construct was an experimental control to normalize for variability in transfection 
efficiency. Multiple dosages of plasmid DNA were used for the luciferase assay to observe an 
increase in the amount of luciferase expressed and thus confirm that the conditions were in the 
dynamic range of the assay.  
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Luciferase Assay 
Using this approach we found A160G and A176G mutations to limit luciferase 
expression significantly relative to the WT sequence in a dosage dependent manner by   ̴50% 
(Figure 9). The T175A also decreased luciferase expression significantly in the 1.0 μg and 2.0 μg 
DNA conditions by   ̴40% (Figure 9). Oddly, the T159A mutation did not significantly achieve a 
decrease of expression. This mutation, although predicted to hinder expression by previous 
studies, did not diminish promoter activity, suggesting that the distal TATA box is not required 
for expression. As expected the vector without a promoter showed almost no luciferase 
expression and the p21 promoter, one of the strongest in the p53 network, effectively induced 
robust luciferase expression.  
 
 
Figure 9: BAIT promoter region activity is decreased by point mutations of the TATA box. Amount of luciferase expressed as 
driven by each of the promoters at the different amounts of DNA, 0.5 ug, 1.0 ug, and 2.0 ug. Respective to the increasing 
micrograms of DNA, the A160G mutation decreased activity by 41%, 44%, 46%. The T175A mutation decreased activity by 33%, 
37% and 36%. The A176G mutation decreased activity by 47%, 55%, and 53%. * Signifies a difference relative to BAIT promoter 
WT insert at each concentration by T-Test with p < .05.  
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In summary, there was an approximate 50% decrease in the TATA box activity of the 
BAIT promoter region when the distal TATA box had either T175A or A176G mutated or the 
proximal TATA box had A160G mutated, demonstrating that these TATA boxes are contributing 
to expression in this system (Figure 9).  
 
Aim 2:  BAIT expression patterns changes among cell types and stimuli.  
Cell types 
BAIT expression was measured in an array of cell lines treated with either DMSO or 
Nutlin (Figure 10). The expression of PUMA is induced in response to Nutlin, a small-molecule 
that leads to p53 stabilization, but inversely, the levels of BAIT expression decreased in every 
cell line (except IMR90 and SJSA) after p53 activation. BAIT expression was greatest in HCT116 
colorectal cancer cells; thus this cell line was used for the remainder of the experiments.  
 
Figure 10: BAIT Expression is detected in 8 cell types and is greatest in HCT116 cell line when exposed to DMSO and Nutlin3R. 
The cells were harvested for RNA at 12 hours post-treatment. The RNA was converted into cDNA using strand-specific primers 
for BAIT. The cDNA were used in qRT-PCR using forward and reverse primers for BAIT and the relative expression was 
normalized to 18s..   
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Stress Stimuli 
We then wanted to see if there was any correlation between BAIT expression and PUMA 
activation in response to stress stimuli. The colorectal cells were exposed to two common DNA-
damaging agents, Gamma-IR and UVC (no exposure for control) (Figure 11).  
 
Figure 11: BAIT Expression in HCT116 cells decreases when exposed to Gamma-IR. (A) qRT-PCR results showed gamma-IR 
exposure significantly decreased BAIT expression by 45%. p21 expression significantly increased 4-fold in Gamma-IR and 2-fold 
in UVC exposure. * Signifies a difference relative to untreated by T-Test with p < .05. (B) At the protein level, western blot 
showed p53 and PUMA were induced under gamma-IR and UVC exposure. Only Gamma-IR exposure induced p21 expression.  
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The subsequent levels of BAIT, PUMA exon 2:3 junction, PUMA exon 3:4 junction, and 
p21 were measured by quantitative RT-PCR analysis (Figure 11A). To measure BAIT, a strand-
specific primer was used to convert the antisense region of PUMA following exon 3 into cDNA 
to pick up the low levels of transcription. The qRT-PCR reaction amplified this region further 
with the BAIT F/R primer. A primer mixture of random primers/OligodTs were used to create 
the cDNA used for the qRT-PCR amplification with the F/R primers for PUMA exon 2:3, PUMA 
exon 3:4, p21, and 18s (Table 3) (Supplementary Figure 1). The protein levels of p53, PUMA, 
and p21 was also measured by immunoblot analysis (Figure 11B).  
Interestingly, when HCT116 cells were treated with Gamma-IR, BAIT expression 
decreased by 45%, but there was no change in BAIT expression in response to UVC.  These cells 
then had p21 induction of about 4-fold. However, there was no impressionable change in 
PUMA mRNA expression at either the exon 2:3 or 3:4 junctions, although its protein expression 
did increase. Also in cells treated with UVC, there was a 2-fold increase in p21 mRNA 
expression, but no discernable increase at the protein level, and the BAIT and PUMA expression 
at both junctions were unaffected.  
HCT116 cells were also treated with DMSO, Nutlin3R or 5FU and the change in RNA 
expression levels of BAIT and PUMA were determined by qRT-PCR (Figure 12A). BAIT expression 
decreased by half in Nutlin3R treatment, but increased 3-fold in 5FU treatment. Unexpectedly, 
both the PUMA exon 2:3 and PUMA exon 3:4 junctions increased about 2-fold in both the 
Nutlin3R and 5FU conditions. Notably, p21 expression increased over 12-fold in both 
treatments as well, indicating a robust p53 response. The activation of stress-response 
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pathways was observed at the protein level as well, as demonstrated by the increase in protein 
expression for p53, PUMA, and p21 (Figure 12B). 
 
Figure 12: BAIT Expression in HCT116 cells treated with Nutlin3R decreases and 5FU increases with an equal effect on PUMA 
expression. HCT116 cells were exposed to 1 μM of Nutlin3R , 375 μM of 5FU, or the equivalent amount of DMSO. (A) Nutlin 3R 
decreased BAIT expression ny half but 5FU increased BAIT 4-fold. Nutlin 3R increased PUMA 2:3 junction 2.3-fold and 3:4 
junction 2.4-fold. 5FU increased PUMA 2:3 junction 1.8-fold and 3:4 junction 2-fold.  Activation of p21 increased 14.6 fold in 
Nutlin3R and 12-fold in 5FU. * Signifies a difference from DMSO by T-Test with p < .05. (B) At the protein level, p53 and PUMA 
were equally expressed in Nutlin and 5FU. Nutlin also induced a larger increase in p21 expression than 5FU treatment.   
 
  Moreover, since antisense transcription was also present in p53 null cells, as observed 
by GRO-seq, this prompted us to test BAIT expression in these cells. We used the RNA 
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harvested from a previous experiment in the lab which treated p53 WT (+/+) cells and p53 null 
(-/-) cells with DMSO, 5FU, or Doxorubicin (Dox) and harvested 12 hours post-treatment. We 
used this RNA to measure BAIT, PUMA, and p21 expression (Figure 13). Unexpectedly, we 
observed a 4.2-fold increase of BAIT expression in p53 null cells when treated with 5FU. This 
suggests that BAIT expression is regulated in a p53-independent manner in this setting. Also in 
p53 WT HCT116 cells, we observed no significant change in BAIT expression in Dox compared to 
DMSO, but observed PUMA exon 2:3 junction expression in both 5FU and Dox treated increase 
greater than 5-fold and increase 8-fold at the PUMA exon 3:4 junction expression.  
 
Figure 13: Increased BAIT expression upon 5FU is independent of p53. (A) Timeline of drug treatment. (B) The HCT116 cells 
were treated with DMSO, 5FU, or Dox.  Cells were harvested at 12 hours post-treatment. In p53 WT cells BAIT expression 
increases 3.5-fold and in p53 null it increases 4.2-fold when treated with 5FU. The expression of PUMA Exon 2:3 junction in p53 
WT increased 5.7-fold in 5FU and 5.4-fold in Dox. The p53 null cells decreased PUMA Exon 2:3 junction expression by 37% in 
Dox treatment. The expression of PUMA Exon 3:4 junction in p53 WT increased 8.07-fold in 5FU and 8.9-fold in Dox treatment. 
p21 expression increased 15.6-fold in 5FU p53 WT, 14.5-fold in Dox p53 WT, 2.7-fold in 5FU p53null, and 2.5 fold in Dox p53 
null. * Signifies a difference from DMSO for each cell-line by T-Test with p < .05. 
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Aim 3: Knockdown of the BAIT transcript changes the relative expression of PUMA. 
 To determine if the BAIT transcript has a function in regulating PUMA expression, the 
BAIT transcript was knocked down using an antisense oligonucleotide (ASO) manufactured by 
ISIS Pharmaceuticals®. Five ASOs targeting sequences at various distances relative to the 
transcription start site (TSS) of BAIT were tested (+18, +22, +46, +182, +610) (Figure 14).  
 
Figure 14: Location of ASOs relative to the transcription start site. The ASOs were generated by ISIS Pharmaceuticals®.  This 
strand is the sense orientation of the PUMA locus around Exon 3. The top purple strand is the ASO sequence that binds to the 
RNA sequence produced from antisense transcription of the bottom purple strand.   
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The ASOs have a DNA sequence that is identical to the sense strand of the PUMA 
sequence, thus complementarily binding the BAIT antisense RNA transcript. The ASOs have a 
phosphorothioate backbone that protects from nuclease degradation. When the ASO-DNA 
duplex is formed with the BAIT RNA, the duplex is degraded by the nuclear RNase-H enzyme.  
A successful transfection with minimal cell death of the non-targeting ASO tagged with 
Texas Red Malemide (NT-TR) into cells was observed with microscopy using 15 uL of 
Lipofectamine LTX + reagent (Supplementary Figure 2). Lipofectamine LTX + treatment alone 
did not significantly change the level of BAIT or PUMA expression (Supplemental Figure 3). The 
5 ASOs were then transfected into cells using Lipofectamine LTX + (vehicle), then treated with 
either DMSO or Nutlin at 12 hours post-transfection and harvested at 24 hours post-
transfection (Figure 15A). BAIT expression, PUMA expression at the 2:3 and 3:4 exon junctions, 
and p21 expression was measured using qRT-PCR analysis (Figure 15B). As anticipated, BAIT 
expression decreased in Nutlin compared to DMSO in conditions with a NT ASO. +18 and +46 
ASOs significantly knocked down BAIT expression in cells exposed to Nutlin. This decrease in 
BAIT expression caused at least 40% reduction of PUMA exon 2:3 and 3:4 junctions in Nutlin. 
Although the knockdown of BAIT in DMSO, by +18, +22, +46, and +182, was reduced by about 
50%, it was not statistically significant. However, the DMSO BAIT knockdowns caused about a 
70% reduction in PUMA exon 2:3 and exon 3:4 junction by 70%. The knockdown of BAIT 
showed a decreased expression in PUMA, suggesting that BAIT contributes to a positive 
regulation of PUMA expression.  
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Figure 15: BAIT expression knockout decreases expression of PUMA E2:E3 and E3:E4 junctions. (A) Timeline of ASO 
experiment. The HCT116 cells were transfected with 200uM of the ASO. At 24 hours they were treated with DMSO or Nutlin. 
Cells were harvested 12 hours post-treatment. (B) Significant reduction in expression: BAIT in Nutlin – +18 (57%) and +46 (63%). 
PUMA E2:E3 junction in DMSO – +18 (73%), +22 (68%), +46 (75%), +182 (67%); in Nutlin – +82 (50%), +46 (47%), +182 (39%). 
PUMA E3:E4 junction in DMSO – +18 (75%), +46 (70%); in Nutlin – +18 (37%), +22 (29%). * Signifies a difference relative to NT – 
specific to DMSO (blue) or Nutlin (red) by T-Test with p < .05. 
 
DISCUSSION 
 The transcription factor p53 is a key tumor suppressor protein that regulates a 
transcriptional program mediating diverse cellular responses to stress including cell cycle arrest 
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and programmed cell death. p21 and PUMA are two main targets of p53 that are induced in the 
presence of cellular stress signals, such as radiation, genotoxic agents, hypoxia, or mutations 
resulting in oncogenic signaling. Both p21 and PUMA harbor the potential to tip the cell 
towards arrest (p21) or apoptosis (PUMA). Since the p53 network is inactivated in over 90% of 
cancers (either by p53 mutation or alterations upstream of p53), these pathways downstream 
of p53 are important to understand for targeted cancer therapies. Investigating p53s gene 
networks could provide insight for new therapeutic strategies that bypass p53 to artificially 
activate desired outcomes such as cell death of cancer cells. This idea has been demonstrated 
by a class of cancer drugs named BH3 mimetics, which act like PUMA and are able to inhibit the 
pro-survival mitochondrial proteins of the intrinsic apoptotic pathway (Chonghaile and Letai 
2009). Attention has also turned to PUMA in hopes of understanding p53-autonomous 
regulatory mechanisms for possible exploitation of new cancer therapies. Using GRO-seq data 
to measure active and strand-specific RNA Pol II movement along the genomic locus of PUMA, 
we found evidence of antisense transcription initiating 6 Kb into the locus (Allen et al. 2014). In 
general, natural antisense transcripts (NATs), such as this one are characterized as being non-
coding RNAs (ncRNAs), which in turn constitute 90% of the transcribed material within the 
genome (Mattick and Makunin 2006; Prasanth and Spector 2007). Currently, much effort is 
devoted to understanding the potential functions these antisense transcripts may have in 
regulating their corresponding sense transcript. Some of the investigated members of this class 
of ncRNAs function by regulating the sense transcript through RNA masking, RNA interference, 
transcriptional interference, and epigenetic modifications (Beiter 2008). Here, I investigated a 
newly identified NAT, dubbed BAIT, as a possible gene-specific regulator of the PUMA locus. 
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 The identification of two putative TATA boxes in close proximity to the transcription 
start site for BAIT antisense transcription identified by GRO-seq prompted an investigation to 
understand if this region was a functional promoter region for BAIT. The proximal and distal 
TATA boxes were engineered to contain single point mutations that modify the third and fourth 
base in the motif, which was previously shown to diminish their activity within the promoter 
(T159A, A160G, T175A, and A176G) (Wobbe and Struhl 1990). The activity of these mutated 
TATA boxes were compared to the WT region using a reporter assay. We observed that the 
activity of the promoter region decreases by about half when either the proximal or distal TATA 
boxes were mutated at the fourth position and when the proximal TATA box contained a T 
switched to an A at the third position. This result suggests that the proximal TATA box within 
the BAIT promoter region is necessary to drive expression in this system, but is inconclusive 
regarding the distal TATA box.   
 Previously it has been reported that the level of antisense transcription fluctuates in 
different cell types and in response to different stimuli (Beiter 2008). Similarly we 
demonstrated this variability in the expression of BAIT. We detected BAIT in all eight cell lines 
tested; however, the level of BAIT expression varied widely among these eight lines. The 
expression ranged over a four-fold difference from A549s, which express BAIT at the lowest 
levels, to HCT116s, which demonstrate the highest levels of BAIT expression. Not only were 
BAIT levels different between cell lines, but its expression level changed in response to different 
stimuli in a single cell line, HCT116. We demonstrated that BAIT expression decreases in 
response to gamma-IR and is unaltered after UVC exposure. These conditions do not increase 
PUMA expression at the RNA level, but they do increase PUMA induction at the protein level. 
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However, this experiment is confounded by the low level of p53 induction in the presence of 
gamma-IR and UVC.   
 Although we observed that BAIT consistently decreases in response to Nutlin, we found 
it increases in response to 5FU. This surprising result increases the complexity of the 
PUMA/BAIT relationship since there are similar increases in p53, PUMA, and p21 at the RNA 
and protein level of cells treated with both Nutlin and 5FU. We expected that activating the 
PUMA locus by p53 would have a similar effect on BAIT regardless of the activating agent. We 
thus wanted to address the expression of BAIT in the absence of p53. We took advantage of 
RNA extracts previously harvested from HCT116 p53 +/+ and -/- cells treated with DMSO, 5FU, 
or Dox, generated by Veronica Dengler of the Espinosa lab. BAIT expression dramatically 
increased as expected in the p53 +/+ cells, but unexpectedly, BAIT expression after 5FU 
exposure in the p53 -/- cells increased immensely. This result demonstrates that BAIT 
expression is not activated by p53 and suggests that additional unknown regulators contribute 
to its expression. The toxic nature of 5FU, a genotoxic agent employed in chemotherapy, could 
potentially induce an additional transcription factor, beyond p53-induced by Nutlin, that is 
promoting or stabilizing the expression of BAIT. 
 To explore the function of BAIT we used antisense oligonucleotides to knockdown BAIT 
in HCT116 p53 +/+ cells exposed to DMSO or Nutlin. Knockdown of BAIT expression by about 
50% in both DMSO and Nutlin, in turn decreased mature PUMA RNA expression as measured by 
both exon 2:3 and 3:4 splice junctions. These data suggest that BAIT contributes to the up-
regulation of PUMA at some point upstream of the 2:3 junction splicing, perhaps at the PUMA 
promoter region. BAIT could potentially do this by recruiting or guiding epigenetic modifiers, 
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such as histone modifications or chromatin remodeling complexes, to regions which promotes 
PUMA expression. To test this hypothesis, chromatin immunoprecipitation (ChIP) analysis of 
histone modificatiers and chromatin complexes at the PUMA locus in cells with the BAIT ASO 
compared to NT, could be employed.  This hypothesis would have to be validated in multiple 
cell lines and in alternative stress conditions. It would also be important to observe BAIT 
knockdown in 5FU, since its expression is upregulated in that condition. Unfortunately, I have 
been unable to achieve a consistent stable knockdown in 5FU. Another angle to manipulate 
BAIT expression would be to create a knockout of BAIT, using CRISPRs designed to delete the 
proximal functional TATA box within the BAIT promoter region.   
 Investigating BAIT as a regulatory NAT for PUMA has provided more questions than 
answers. Regrettably, I am unable to provide a specific mechanism in which knockdown of BAIT 
causes a reduction of PUMA expression, but this study has provided initial evidence for a 
functional regulatory SAS pair within the PUMA locus. Adding natural antisense transcription as 
an additional level to gene regulation provides an alternative way to approach cancer therapies. 
Thus, if further investigation revealed a mechanism by which BAIT is able to regulate PUMA 
expression, it could add an alternative angle to activate PUMA, and thus cell death, in cancer 
cells. 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1: BBC3 (PUMA) Locus. The PUMA locus showing a compilation of the important features and regions 
referred to in this thesis.   
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Supplementary Figure 2: 15ul Lipofectamine is optimal for an effective transfection and minimal cell death. The NT ASO with 
a Texas Red tag was created for a control to observe which amount (15μl of 25 μl) of Lipofectamine LTX + was required for 
uptake of the ASO into the cell with the least toxicity.  
 
 
 
Supplementary Figure 3: Lipofectamine LTX + reagent does not affect BAIT, PUMA, or p21 expression. qRT-PCR analysis 
showed no significant change in BAIT, PUMA exon 2:3 and 3:4, and p21 levels in Lipo / LTX + compared to untreated.  This is the 
same blot as Figure 11 but including the Lipo/LTX well. * Signifies a difference from the untreated by T-Test with p < .05. 
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